Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (8): 686-691.DOI: 10.3969/j.issn.1673-8640.2018.08.005
• Orginal Article • Previous Articles Next Articles
LIU Sichao, YAN Hongli
Received:
2017-10-10
Online:
2018-08-10
Published:
2018-09-07
CLC Number:
LIU Sichao, YAN Hongli. Correlation of angiogenesis regulation factors and oxidative stress markers with adverse pregnancy in preeclampsia patients[J]. Laboratory Medicine, 2018, 33(8): 686-691.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.08.005
组别 | 例数 | 年龄 (岁) | 分娩次数 | 妊娠次数 | |||||
---|---|---|---|---|---|---|---|---|---|
初次[例(%)] | 2次[例(%)] | ≥3次[例(%)] | 1次[例(%)] | 2次[例(%)] | ≥3次[例(%)] | ||||
对照组 | 50 | 30.6±0.6 | 21(42.0) | 13(26.0) | 16(32.0) | 12(24.0) | 18(36.0) | 20(40.0) | |
GH组 | 65 | 30.5±0.8 | 25(38.5) | 14(21.5) | 26(40.0) | 18(27.7) | 13(20.0) | 34(52.3) | |
PE组 | 84 | 30.9±0.7 | 42(50.0) | 17(20.2) | 25(29.8) | 30(35.7) | 33(39.3) | 21(25.0) | |
P值 | 0.899 | 0.582 | 0.009 | ||||||
组别 | 剖宫产史[例(%)] | 流产史[例(%)] | 收缩压(kPa) | 舒张压 (kPa) | 尿蛋白(g/L) | ||||
对照组 | 5(10.0) | 20(40.0) | 14.94±0.26 | 9.15±0.23 | 0.01±0.00 | ||||
GH组 | 12(18.5) | 29(44.6) | 21.21±0.29 | 13.78±0.28 | 0.15±0.00 | ||||
PE组 | 41(48.8) | 64(76.2) | 22.12±0.28 | 14.48±0.24 | 2.06±0.09 | ||||
P值 | <0.001 | 0.020 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 年龄 (岁) | 分娩次数 | 妊娠次数 | |||||
---|---|---|---|---|---|---|---|---|---|
初次[例(%)] | 2次[例(%)] | ≥3次[例(%)] | 1次[例(%)] | 2次[例(%)] | ≥3次[例(%)] | ||||
对照组 | 50 | 30.6±0.6 | 21(42.0) | 13(26.0) | 16(32.0) | 12(24.0) | 18(36.0) | 20(40.0) | |
GH组 | 65 | 30.5±0.8 | 25(38.5) | 14(21.5) | 26(40.0) | 18(27.7) | 13(20.0) | 34(52.3) | |
PE组 | 84 | 30.9±0.7 | 42(50.0) | 17(20.2) | 25(29.8) | 30(35.7) | 33(39.3) | 21(25.0) | |
P值 | 0.899 | 0.582 | 0.009 | ||||||
组别 | 剖宫产史[例(%)] | 流产史[例(%)] | 收缩压(kPa) | 舒张压 (kPa) | 尿蛋白(g/L) | ||||
对照组 | 5(10.0) | 20(40.0) | 14.94±0.26 | 9.15±0.23 | 0.01±0.00 | ||||
GH组 | 12(18.5) | 29(44.6) | 21.21±0.29 | 13.78±0.28 | 0.15±0.00 | ||||
PE组 | 41(48.8) | 64(76.2) | 22.12±0.28 | 14.48±0.24 | 2.06±0.09 | ||||
P值 | <0.001 | 0.020 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 胎先露部位 | 胎盘前置 | 胎盘剥落 | IUFD | IUGR | APH | PPROM | |
---|---|---|---|---|---|---|---|---|---|
头部 | 臀部 | ||||||||
对照组 | 50 | 50(100.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(2.0) | 0(0.0) | 0(0.0) |
GH组 | 65 | 60(92.3) | 5(7.7) | 5(7.7) | 1(0.15) | 6(9.2) | 8(12.3) | 2(3.1) | 0(0.0) |
PE组 | 84 | 64(76.2) | 20(23.8)* | 12(14.3)* | 19(22.6)* | 32(38.1)* | 35(41.7)* | 17(20.2)* | 10(11.9)* |
组别 | 阴道分娩 | 剖宫产 | 死胎 | 早产 | 产程延长 | PPH | 产妇死亡 | ||
对照组 | 49(98.0) | 1(2.0) | 0(0.0) | 2(4.0) | 5(10.0) | 3(6.0) | 0(0.0) | ||
GH组 | 50(76.9) | 15(23.1)* | 4(6.2) | 47(72.3)* | 15(23.1) | 5(7.7) | 0(0.0) | ||
PE组 | 7(8.3) | 77(91.7)* | 10(11.9)* | 76(90.5)* | 17(20.2) | 13(15.5)* | 2(2.4)* |
组别 | 例数 | 胎先露部位 | 胎盘前置 | 胎盘剥落 | IUFD | IUGR | APH | PPROM | |
---|---|---|---|---|---|---|---|---|---|
头部 | 臀部 | ||||||||
对照组 | 50 | 50(100.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 1(2.0) | 0(0.0) | 0(0.0) |
GH组 | 65 | 60(92.3) | 5(7.7) | 5(7.7) | 1(0.15) | 6(9.2) | 8(12.3) | 2(3.1) | 0(0.0) |
PE组 | 84 | 64(76.2) | 20(23.8)* | 12(14.3)* | 19(22.6)* | 32(38.1)* | 35(41.7)* | 17(20.2)* | 10(11.9)* |
组别 | 阴道分娩 | 剖宫产 | 死胎 | 早产 | 产程延长 | PPH | 产妇死亡 | ||
对照组 | 49(98.0) | 1(2.0) | 0(0.0) | 2(4.0) | 5(10.0) | 3(6.0) | 0(0.0) | ||
GH组 | 50(76.9) | 15(23.1)* | 4(6.2) | 47(72.3)* | 15(23.1) | 5(7.7) | 0(0.0) | ||
PE组 | 7(8.3) | 77(91.7)* | 10(11.9)* | 76(90.5)* | 17(20.2) | 13(15.5)* | 2(2.4)* |
组别 | 例数 | PLGF(pg/mL) | sFlt-1(pg/mL) |
---|---|---|---|
对照组 | |||
基线时 | 50 | 136.4(88.0~177.6) | 119.8(88.6~161.5) |
分娩后48 h | 50 | 188.7(131.1~215.1)△△ | 44.9(19.4~88.5)△△ |
GH组 | |||
基线时 | 65 | 52.9(37.6~5.1)* | 414.1(165.2~630.9)* |
分娩后48 h | 65 | 164.3(93.9~201.2)△△ | 77.6(45.3~102.7)△△ |
PE组 | |||
基线时 | 84 | 21.4(12.5~48.5)*# | 788.4(510.1~919.3)*# |
分娩后48 h | 84 | 96.8(77.5~132.4)△△ | 105.0(66.7~141.8)△△ |
组别 | sFlt-1/PLGF比值 | 8-epi-PGF2α(pg/mL) | TAC(mmol/L) |
对照组 | |||
基线时 | 0.9(0.6~1.2) | 35.7(28.7~43.0) | 1.1(1.0~1.2) |
分娩后48 h | 0.2(0.2~0.5)△△ | 15.3(12.4~18.7)△△ | 1.2(1.2~1.4)△ |
GH组 | |||
基线时 | 7.9(5.4~12.9) | 198.7(93.0~394.6) | 0.6(0.4~0.8) |
分娩后48 h | 0.5(0.2~0.7)△△ | 18.4(12.2~32.2)△△ | 0.9(0.6~1.2)△ |
PE组 | |||
基线时 | 36.8(16.4~56.9)*# | 321.8(195.8~616.4)*# | 0.5(0.3~0.6)*# |
分娩后48 h | 1.2(0.3~2.1)△△ | 66.4(32.6~101.2)△△ | 0.8(0.4~0.9)△△ |
组别 | 例数 | PLGF(pg/mL) | sFlt-1(pg/mL) |
---|---|---|---|
对照组 | |||
基线时 | 50 | 136.4(88.0~177.6) | 119.8(88.6~161.5) |
分娩后48 h | 50 | 188.7(131.1~215.1)△△ | 44.9(19.4~88.5)△△ |
GH组 | |||
基线时 | 65 | 52.9(37.6~5.1)* | 414.1(165.2~630.9)* |
分娩后48 h | 65 | 164.3(93.9~201.2)△△ | 77.6(45.3~102.7)△△ |
PE组 | |||
基线时 | 84 | 21.4(12.5~48.5)*# | 788.4(510.1~919.3)*# |
分娩后48 h | 84 | 96.8(77.5~132.4)△△ | 105.0(66.7~141.8)△△ |
组别 | sFlt-1/PLGF比值 | 8-epi-PGF2α(pg/mL) | TAC(mmol/L) |
对照组 | |||
基线时 | 0.9(0.6~1.2) | 35.7(28.7~43.0) | 1.1(1.0~1.2) |
分娩后48 h | 0.2(0.2~0.5)△△ | 15.3(12.4~18.7)△△ | 1.2(1.2~1.4)△ |
GH组 | |||
基线时 | 7.9(5.4~12.9) | 198.7(93.0~394.6) | 0.6(0.4~0.8) |
分娩后48 h | 0.5(0.2~0.7)△△ | 18.4(12.2~32.2)△△ | 0.9(0.6~1.2)△ |
PE组 | |||
基线时 | 36.8(16.4~56.9)*# | 321.8(195.8~616.4)*# | 0.5(0.3~0.6)*# |
分娩后48 h | 1.2(0.3~2.1)△△ | 66.4(32.6~101.2)△△ | 0.8(0.4~0.9)△△ |
组别 | PLGF(pg/mL) | sFlt-1(pg/mL) | sFlt-1/PLGF比值 | 8-epi-PGF2α(pg/mL) | TAC(mmol/L) |
---|---|---|---|---|---|
PE组 | 45.25±2.32 | 548.4±10.3 | 17.22±0.89 | 245.2±14.7 | 0.58±0.01 |
PE合并IUFD组 | 18.71±1.24* | 741.7±13.9* | 49.64±1.37* | 498.9±15.1* | 0.40±0.02* |
PE合并胎盘剥落组 | 28.08±1.69* | 685.4±12.7* | 25.63±1.08* | 484.7±13.3* | 0.52±0.04* |
PE合并胎盘前置组 | 31.21±1.52* | 581.1±13.2 | 20.87±0.99 | 401.2±12.9* | 0.57±0.03 |
HELLP综合征组 | 17.43±1.64* | 784.9±14.5* | 39.78±1.14* | 489.7±15.2* | 0.41±0.02* |
PE合并IUGR组 | 16.29±1.53* | 896.7±15.0* | 42.79±1.44* | 499.3±14.7* | 0.33±0.04* |
组别 | PLGF(pg/mL) | sFlt-1(pg/mL) | sFlt-1/PLGF比值 | 8-epi-PGF2α(pg/mL) | TAC(mmol/L) |
---|---|---|---|---|---|
PE组 | 45.25±2.32 | 548.4±10.3 | 17.22±0.89 | 245.2±14.7 | 0.58±0.01 |
PE合并IUFD组 | 18.71±1.24* | 741.7±13.9* | 49.64±1.37* | 498.9±15.1* | 0.40±0.02* |
PE合并胎盘剥落组 | 28.08±1.69* | 685.4±12.7* | 25.63±1.08* | 484.7±13.3* | 0.52±0.04* |
PE合并胎盘前置组 | 31.21±1.52* | 581.1±13.2 | 20.87±0.99 | 401.2±12.9* | 0.57±0.03 |
HELLP综合征组 | 17.43±1.64* | 784.9±14.5* | 39.78±1.14* | 489.7±15.2* | 0.41±0.02* |
PE合并IUGR组 | 16.29±1.53* | 896.7±15.0* | 42.79±1.44* | 499.3±14.7* | 0.33±0.04* |
项目 | 分娩前并发症 | 分娩后不良结局 | ||||
---|---|---|---|---|---|---|
IUGR | 胎盘剥落/前置 | IUFD | 死胎 | PPH | ||
PLGF | ||||||
r值 | -0.422 | -0.671 | -0.701 | -0.372 | -0.301 | |
P值 | 0.003 | <0.001 | <0.001 | 0.017 | 0.040 | |
sFlt-1 | ||||||
r值 | 0.552 | 0.688 | 0.733 | 0.741 | 0.481 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.004 | |
8-epi-PGF2α | ||||||
r值 | 0.616 | 0.582 | 0.644 | 0.701 | 0.408 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.005 | |
TAC | ||||||
r值 | -0.641 | -0.755 | -0.824 | -0.819 | -0.501 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.004 |
项目 | 分娩前并发症 | 分娩后不良结局 | ||||
---|---|---|---|---|---|---|
IUGR | 胎盘剥落/前置 | IUFD | 死胎 | PPH | ||
PLGF | ||||||
r值 | -0.422 | -0.671 | -0.701 | -0.372 | -0.301 | |
P值 | 0.003 | <0.001 | <0.001 | 0.017 | 0.040 | |
sFlt-1 | ||||||
r值 | 0.552 | 0.688 | 0.733 | 0.741 | 0.481 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.004 | |
8-epi-PGF2α | ||||||
r值 | 0.616 | 0.582 | 0.644 | 0.701 | 0.408 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.005 | |
TAC | ||||||
r值 | -0.641 | -0.755 | -0.824 | -0.819 | -0.501 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.004 |
项目 | 分娩前并发症 | 分娩后不良结局 | ||||
---|---|---|---|---|---|---|
IUGR | 胎盘剥落/前置 | IUFD | 死胎 | PPH | ||
PLGF | ||||||
r值 | -0.103 | -0.032 | -0.192 | -0.064 | -0.055 | |
P值 | 0.061 | 0.694 | 0.070 | 0.485 | 0.188 | |
sFlt-1 | ||||||
r值 | 0.026 | 0.042 | 0.153 | 0.002 | 0.018 | |
P值 | 0.922 | 0.255 | 0.091 | 0.903 | 0.401 | |
8-epi-PGF2α | ||||||
r值 | 0.008 | 0.023 | 0.084 | 0.109 | 0.183 | |
P值 | 0.806 | 0.899 | 0.721 | 0.279 | 0.309 | |
TAC | ||||||
r值 | -0.210 | -0.110 | -0.188 | -0.188 | -0.161 | |
P值 | 0.188 | 0.440 | 0.182 | 0.446 | 0.154 |
项目 | 分娩前并发症 | 分娩后不良结局 | ||||
---|---|---|---|---|---|---|
IUGR | 胎盘剥落/前置 | IUFD | 死胎 | PPH | ||
PLGF | ||||||
r值 | -0.103 | -0.032 | -0.192 | -0.064 | -0.055 | |
P值 | 0.061 | 0.694 | 0.070 | 0.485 | 0.188 | |
sFlt-1 | ||||||
r值 | 0.026 | 0.042 | 0.153 | 0.002 | 0.018 | |
P值 | 0.922 | 0.255 | 0.091 | 0.903 | 0.401 | |
8-epi-PGF2α | ||||||
r值 | 0.008 | 0.023 | 0.084 | 0.109 | 0.183 | |
P值 | 0.806 | 0.899 | 0.721 | 0.279 | 0.309 | |
TAC | ||||||
r值 | -0.210 | -0.110 | -0.188 | -0.188 | -0.161 | |
P值 | 0.188 | 0.440 | 0.182 | 0.446 | 0.154 |
[1] | 黄引平. 子痫前期与代谢性疾病[J]. 中国计划生育和妇产科,2014,6(1):9-12. |
[2] | 周宇恒,牛建民,段冬梅,等. 子痫前期孕妇产后高血压发生风险及相关因素[J]. 中华心血管病杂志,2014,42(7):603-608. |
[3] | ELKHOLI D G E Y,NAGY H M. Maternal serum concentrations of angiogenic and antiangiogenic factors in threatened miscarriage at 7-12 weeks' gestation and the risk of adverse pregnancy outcomes[J]. Middle East Fertil Soc J,2013,18(3): 208-213. |
[4] | HSIEH T T,CHEN S F,LO L M,et al.The association between maternal oxidative stress at mid-gestation and subsequent pregnancy complications[J]. Reprod Sci,2012,19(5):505-512. |
[5] | GHOSH S K,RAHEJA S,TULI A,et al.Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction? Aprospective cohort study[J]. J Obstet Gynaecol Res,2013,39(5):881-890. |
[6] | 李晓,俞生林, 高沙沙,等. 126例早产儿住院期间宫外生长情况评估[J]. 中国儿童保健杂志,2014,22(5):511-514. |
[7] | 边旭明. 先兆子痫的预测:血管生成调节因子[J]. 中国产前诊断杂志(电子版),2012,4(3):15. |
[8] | RANA S,POWE C E,SALAHUDDIN S,et al.Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia[J]. Circulation,2012,125(7):911-919. |
[9] | 徐又先,濮德敏. 氧化应激在妊娠方面的研究进展[J]. 中国优生与遗传杂志,2012,20(12):7-9. |
[10] | 陈冬微,罗利飞. 妊娠高血压综合征患者治疗前后氧化应激状态的变化[J]. 中国药物与临床,2012,12(4):475-476. |
[11] | 刘俊涛,宋英娜. 子痫前期中的氧化应激和抗氧化治疗[J]. 中国实用妇科与产科杂志,2014,30(10):761-764. |
[12] | DUTTA E H,BEHNIA F,BOLDOGH I,et al.Oxidative stress damage-associated molecular signaling pathways differentiate spontaneous preterm birth and preterm premature rupture of the membranes[J]. Mol Hum Reprod,2016,22(2):143-157. |
[13] | XIN L,WANG J,WU Y,et al.Increased oxidative stress and activated heat shock proteins in human cell lines by silver nanoparticles[J]. Hum Exp Toxicol,2015,34(3):315-323. |
[14] | LYMPERAKI E,TSIKOPOULOS A,MAKEDOU K,et al.Impact of iron and folic acid supplementation on oxidative stress during pregnancy[J]. J Obstet Gynaecol,2015,35(8):803-806. |
[1] | DUAN Yuping, XIE Li, CAI Leiming, WU Jingjing, HONG Mao, LI Qian. Correlation of serum exosomes,placental exosomes and exosomal miR-210 with preeclampsia [J]. Laboratory Medicine, 2022, 37(8): 715-719. |
[2] | WANG Yongbin, LU Kuiying, SU Yong, ZHANG Jun, LIU Fudi. Changes and clinical significance of liver function and oxidative stress in patients with nonalcoholic fatty liver [J]. Laboratory Medicine, 2020, 35(9): 903-907. |
[3] | XU Zhen, MA Lijuan, WU Siyi, WANG Yan, JIA Keke. Predictive role of serum fibronectin level in the second trimester of pregnancy for patients with gestational diabetes mellitus complicated with preeclampsia [J]. Laboratory Medicine, 2020, 35(6): 561-565. |
[4] | CAO Zheng, DONG Ying, ZHAO Shenglong, WANG Jing, ZHANG Chunhong, CHEN Lu, LIU Jingrui, SHEN Min, ZHAI Yanhong, LIU Xiaowei. Utility of non-targeted lipidomics in predicting preeclampsia [J]. Laboratory Medicine, 2020, 35(2): 100-107. |
[5] | YANG Wenwei, YUE Chaoyan. Blood lipid levels and risk factors in pregnant women with preeclampsia during the second trimester pregnancy [J]. Laboratory Medicine, 2017, 32(5): 378-381. |
[6] | LI Meizhu, ZHU Changlin, HUANG Shuxuan, CHEN Shean, LI Weixuan. Determination and clinical significance of serum oxidative stress indicators in patients with cerebral stroke [J]. Laboratory Medicine, 2016, 31(1): 38-41. |
[7] | LI Qian, LONG Anxiong, HONG Mao, CAI Leiming, XIE Li, GU Ji'an, TAN Longyi.. The analysis of serum miR-520g expression in the early stage of preeclampsia among pregnant patients [J]. Laboratory Medicine, 2015, 30(4): 345-348. |
[8] | SHAO Yun, QIN Xiaoxia, WEI Congzhen, ZHANG Qiufen, SHAO Ming, YAN Guochao. Influence of alpha-lipoic acid on serum adipocytokines in a rat model of dietary-induced obesity [J]. Laboratory Medicine, 2015, 30(11): 1147-1149. |
[9] | ZHANG Yan,CHEN Xiaoting,SONG Huizhu,QI Zhigang. Research progress on molecular pathogenesis of obesity-induced insulin resistance [J]. , 2014, 29(7): 774-777. |
[10] | ZHU Yuli, LI Qian, CHEN Xiong, LU Shuaijun, LONG Anxiong, TAN Longyi.. Changes and significance of plasma fibrinogen γ levels in preeclampsia pregnant women [J]. , 2014, 29(5): 468-471. |
[11] | JIANG Xingliang, LIU Sulan, YI Tingting.. Research on the parameters of oxidative stress in patients with hyperhomocysteinemia [J]. , 2014, 29(2): 125-129. |
[12] | SUN Li, YU Qiongyan, CHEN Ying, LI Dashuai, YU Jing, GONG Bo. The correlation analysis between fibrinogen and preeclampsia [J]. , 2014, 29(11): 1112-1114. |
[13] | YU Miao,ZHANG Li,QIN Bing.. The clinical significance of serum cystatin C in the diagnosis of severe preeclampsia [J]. , 2013, 28(6): 471-474. |
[14] | JIAO Ruibao1,FENG Hengxiao2,TANG Jibin1,FANG Jun3,FENG Junrong4,ZHAN Sanhua5,ZHOU Ping1,CHEN Ran1.. Influence of seminal oxidative stress on sperm DNA integrity and other parameters in males with infertility [J]. , 2013, 28(6): 487-491. |
[15] | LIU Xiaohua,CHENG Weiwei. The predictive significance on the detection of coagulation andfibrinolysis related itemsfor late on set preeclampsia among pregnant women during their 32-33 gestational weeks [J]. , 2012, 27(12): 1024-1026. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||